image
Healthcare - Biotechnology - NASDAQ - US
$ 24.55
8.53 %
$ 18.2 B
Market Cap
-72.21
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SMMT stock under the worst case scenario is HIDDEN Compared to the current market price of 24.6 USD, Summit Therapeutics Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SMMT stock under the base case scenario is HIDDEN Compared to the current market price of 24.6 USD, Summit Therapeutics Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SMMT stock under the best case scenario is HIDDEN Compared to the current market price of 24.6 USD, Summit Therapeutics Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SMMT

image
$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0$15.0$15.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
313 K OPERATING INCOME
100.35%
-221 M NET INCOME
64.01%
-142 M OPERATING CASH FLOW
-85.13%
-205 M INVESTING CASH FLOW
65.06%
381 M FINANCING CASH FLOW
340.66%
0 REVENUE
0.00%
-66.9 M OPERATING INCOME
-1.89%
-62.9 M NET INCOME
-2.79%
-61.2 M OPERATING CASH FLOW
-25.67%
160 M INVESTING CASH FLOW
91.79%
7.68 M FINANCING CASH FLOW
132.51%
Balance Sheet Summit Therapeutics Inc.
image
Current Assets 424 M
Cash & Short-Term Investments 412 M
Receivables 557 K
Other Current Assets 10.8 M
Non-Current Assets 11.8 M
Long-Term Investments 0
PP&E 7.4 M
Other Non-Current Assets 4.41 M
94.67 %Total Assets$435.6m
Current Liabilities 41.7 M
Accounts Payable 4.64 M
Short-Term Debt 3.76 M
Other Current Liabilities 33.3 M
Non-Current Liabilities 5.08 M
Long-Term Debt 0
Other Non-Current Liabilities 5.08 M
9.90 %8.04 %71.20 %10.86 %Total Liabilities$46.8m
EFFICIENCY
Earnings Waterfall Summit Therapeutics Inc.
image
Revenue 0
Cost Of Revenue 15 M
Gross Profit -15 M
Operating Expenses 211 M
Operating Income 313 K
Other Expenses 222 M
Net Income -221 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)0(15m)(15m)(211m)313k(222m)(221m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-56.93% ROE
-56.93%
-50.81% ROA
-50.81%
0.08% ROIC
0.08%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Summit Therapeutics Inc.
image
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -221 M
Depreciation & Amortization 89 K
Capital Expenditures -139 K
Stock-Based Compensation 51 M
Change in Working Capital 15.5 M
Others 25.6 M
Free Cash Flow -142 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Summit Therapeutics Inc.
image
Wall Street analysts predict an average 1-year price target for SMMT of $37.2 , with forecasts ranging from a low of $23 to a high of $45 .
SMMT Lowest Price Target Wall Street Target
23 USD -6.31%
SMMT Average Price Target Wall Street Target
37.2 USD 51.62%
SMMT Highest Price Target Wall Street Target
45 USD 83.30%
Price
Max Price Target
Min Price Target
Average Price Target
4545404035353030252520201515101055Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Summit Therapeutics Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
2 Soaring Stocks With More Upside Potential to Buy and Hold Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends. fool.com - 1 week ago
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain Summit Therapeutics is in advanced talks with AstraZeneca for a potential $15B licensing deal for ivonescimab, boosting its cash runway and strategic position. Ivonescimab shows strong PFS data versus Keytruda in NSCLC, but mixed OS results could delay U.S. approval and complicate regulatory pathways. Summit is doubling down on ivonescimab, expanding clinical collaborations and targeting a $90B addressable market beyond NSCLC. seekingalpha.com - 1 week ago
Why Summit Therapeutics Stock Soared 8% Higher Today One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics (SMMT 8.18%) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped by 8%, on a media report that a well-known peer was interested in a licensing deal. fool.com - 1 week ago
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 63% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 week ago
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors REDWOOD CITY, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs, today announced the companies have entered into a clinic. businesswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 4 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ:SMMT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 4 weeks ago
8. Profile Summary

Summit Therapeutics Inc. SMMT

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 18.2 B
Dividend Yield 0.00%
Description Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Contact One Broadway, Cambridge, MA, 02142 https://www.summittxinc.com
IPO Date March 5, 2015
Employees 159
Officers Dr. Mahkam Zanganeh D.D.S., M.B.A. Co-Chief Executive Officer, President & Director Mr. Manmeet Singh Soni CPA Chief Operating Officer, Chief Financial Officer & Director Dr. Fong Clow Chief Biometrics Officer Ms. Shelley D. Spray Chief Education & Brand Officer Dr. Urte Gayko Ph.D. Chief Regulatory, Quality & Pharmacovigilance Officer Dr. Laura Q. M. Chow M.D. Senior Vice President of Clinical Development Mr. Robert W. Duggan Co-Chief Executive Officer & Executive Chairman Prof. Dame Kay Davies DBE, FRS CBE Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor Mr. Dave Gancarz Chief Business & Strategy Officer Dr. Allen S. Yang M.D., Ph.D. Chief Medical Officer